Natus Medical Company Profile (NASDAQ:BABY)

About Natus Medical (NASDAQ:BABY)

Natus Medical logoNatus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company's product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company is organized into three strategic business units: Neurology, Newborn Care and Otometrics.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:BABY
  • CUSIP: 63905010
  • Web:
  • Market Cap: $1.32267 billion
  • Outstanding Shares: 32,528,000
Average Prices:
  • 50 Day Moving Avg: $37.15
  • 200 Day Moving Avg: $36.12
  • 52 Week Range: $31.65 - $43.85
  • Trailing P/E Ratio: 69.50
  • Foreward P/E Ratio: 20.25
  • P/E Growth: 1.08
Sales & Book Value:
  • Annual Revenue: $445.49 million
  • Price / Sales: 2.93
  • Book Value: $13.11 per share
  • Price / Book: 3.06
  • EBITDA: $48 million
  • Net Margins: -4.12%
  • Return on Equity: -4.77%
  • Return on Assets: -2.99%
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 3.33%
  • Quick Ratio: 2.52%
  • Average Volume: 372,828 shs.
  • Beta: 0.95
  • Short Ratio: 6.68

Frequently Asked Questions for Natus Medical (NASDAQ:BABY)

What is Natus Medical's stock symbol?

Natus Medical trades on the NASDAQ under the ticker symbol "BABY."

How were Natus Medical's earnings last quarter?

Natus Medical Inc (NASDAQ:BABY) released its quarterly earnings data on Wednesday, July, 26th. The company reported $0.34 EPS for the quarter, beating the Zacks' consensus estimate of $0.33 by $0.01. The business earned $122.20 million during the quarter, compared to analysts' expectations of $121.99 million. Natus Medical had a negative net margin of 4.12% and a negative return on equity of 4.77%. The firm's quarterly revenue was up 27.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.39 EPS. View Natus Medical's Earnings History.

When will Natus Medical make its next earnings announcement?

Natus Medical is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Natus Medical.

What guidance has Natus Medical issued on next quarter's earnings?

Natus Medical updated its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share guidance of $1.70-1.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.70. The company issued revenue guidance of $505-510 million, compared to the consensus revenue estimate of $504.56 million.Natus Medical also updated its Q3 guidance to $0.37-0.38 EPS.

Where is Natus Medical's stock going? Where will Natus Medical's stock price be in 2017?

3 brokers have issued 1-year target prices for Natus Medical's shares. Their forecasts range from $48.00 to $48.00. On average, they anticipate Natus Medical's stock price to reach $48.00 in the next year. View Analyst Ratings for Natus Medical.

Who are some of Natus Medical's key competitors?

Who are Natus Medical's key executives?

Natus Medical's management team includes the folowing people:

  • Robert A. Gunst, Independent Chairman of the Board
  • James B. Hawkins, President, Chief Executive Officer, Director
  • Jonathan A. Kennedy, Chief Financial Officer, Executive Vice President, IR Contact Officer
  • Austin F. Noll III, Vice President and General Manager - Neurology Strategic Business Unit
  • D. Christopher Chung M.D., Vice President - Medical Affairs, Quality & Regulatory
  • Doris E. Engibous, Independent Director
  • Kenneth E. Ludlum, Independent Director
  • William M. Moore Jr., Independent Director
  • Barbara R. Paul M.D., Independent Director

Who owns Natus Medical stock?

Natus Medical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Diamond Hill Capital Management Inc. (1.63%) and Eqis Capital Management Inc. (0.05%). Company insiders that own Natus Medical stock include Austin Francis Noll III, Dong Chune Christopher Chung, Doris Engibous, James B Hawkins, Jonathan Kennedy, Ken Ludlum, Kenneth M Traverso, Robert A Gunst and William M Moore. View Institutional Ownership Trends for Natus Medical.

Who sold Natus Medical stock? Who is selling Natus Medical stock?

Natus Medical's stock was sold by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc.. Company insiders that have sold Natus Medical stock in the last year include Doris Engibous, Jonathan Kennedy, Robert A Gunst and William M Moore. View Insider Buying and Selling for Natus Medical.

Who bought Natus Medical stock? Who is buying Natus Medical stock?

Natus Medical's stock was purchased by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Natus Medical.

How do I buy Natus Medical stock?

Shares of Natus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Natus Medical's stock price today?

One share of Natus Medical stock can currently be purchased for approximately $40.10.

MarketBeat Community Rating for Natus Medical (NASDAQ BABY)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  229
MarketBeat's community ratings are surveys of what our community members think about Natus Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Natus Medical (NASDAQ:BABY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $48.00 (19.70% upside)
Consensus Price Target History for Natus Medical (NASDAQ:BABY)
Price Target History for Natus Medical (NASDAQ:BABY)
Analysts' Ratings History for Natus Medical (NASDAQ:BABY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/1/2017Benchmark Co.Reiterated RatingBuy -> Buy$55.00 -> $48.00MediumView Rating Details
2/2/2017Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
12/16/2016Off Wall StreetInitiated CoverageSellN/AView Rating Details
4/21/2016Roth CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Natus Medical (NASDAQ:BABY)
Earnings by Quarter for Natus Medical (NASDAQ:BABY)
Earnings History by Quarter for Natus Medical (NASDAQ BABY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.38N/AView Earnings Details
7/26/2017Q2 2017$0.33$0.34$121.99 million$122.20 millionViewN/AView Earnings Details
4/26/2017Q1 2017$0.33$0.30$122.45 million$124.70 millionViewN/AView Earnings Details
2/1/2017Q416$0.53$0.51$107.58 million$107.70 millionViewListenView Earnings Details
10/19/2016Q316$0.34$0.39$89.94 million$90.90 millionViewListenView Earnings Details
7/20/2016Q216$0.36$0.39$92.71 million$96.00 millionViewListenView Earnings Details
4/20/2016Q116$0.30$0.34$90.47 million$87.30 millionViewListenView Earnings Details
1/27/2016Q415$0.46$0.51$100.88 million$100.00 millionViewListenView Earnings Details
10/21/2015Q315$0.38$0.39$93.70 million$94.60 millionViewListenView Earnings Details
7/22/2015Q215$0.32$0.34$90.83 million$91.90 millionViewListenView Earnings Details
4/22/2015Q115$0.29$0.31$88.93 million$89.40 millionViewListenView Earnings Details
1/28/2015Q414$0.38$0.40$93.28 million$94.00 millionViewListenView Earnings Details
10/22/2014Q314$0.31$0.33$87.30 million$89.90 millionViewListenView Earnings Details
7/23/2014Q214$0.26$0.28$84.85 million$86.30 millionViewListenView Earnings Details
4/23/2014Q114$0.23$0.26$84.70 million$85.60 millionViewListenView Earnings Details
1/29/2014Q413$0.32$0.37$89.12 million$90.60 millionViewListenView Earnings Details
10/24/2013Q313$0.19$0.30$80.83 million$85.40 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.14$0.21$83.50 million$82.30 millionViewListenView Earnings Details
5/20/2013Q1 2013$0.11$0.15$84.47 million$85.80 millionViewListenView Earnings Details
2/28/2013Q4 2012$0.26$0.29$93.60 million$90.50 millionViewListenView Earnings Details
11/7/2012$0.14$0.15$81.37 million$80.70 millionViewN/AView Earnings Details
7/26/2012$0.11$0.12ViewN/AView Earnings Details
4/26/2012$0.05$0.07ViewN/AView Earnings Details
2/28/2012$0.12$0.14ViewN/AView Earnings Details
10/27/2011$0.06$0.07ViewN/AView Earnings Details
7/28/2011$0.18$0.13ViewN/AView Earnings Details
4/28/2011$0.11$0.13ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Natus Medical (NASDAQ:BABY)
2017 EPS Consensus Estimate: $1.80
2018 EPS Consensus Estimate: $2.01
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.32$0.32$0.32
Q2 20171$0.38$0.38$0.38
Q3 20171$0.42$0.42$0.42
Q4 20172$0.68$0.68$0.68
Q1 20181$0.39$0.39$0.39
Q2 20181$0.48$0.48$0.48
Q3 20181$0.49$0.49$0.49
Q4 20181$0.65$0.65$0.65
(Data provided by Zacks Investment Research)


Dividend History for Natus Medical (NASDAQ:BABY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Natus Medical (NASDAQ:BABY)
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 92.66%
Insider Trades by Quarter for Natus Medical (NASDAQ:BABY)
Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)
Insider Trades by Quarter for Natus Medical (NASDAQ:BABY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2017Robert A GunstDirectorSell4,400$35.17$154,748.00View SEC Filing  
8/14/2017William M MooreDirectorSell3,000$34.10$102,300.00View SEC Filing  
6/15/2017James B HawkinsInsiderBuy4,000$33.98$135,920.00View SEC Filing  
5/31/2017James B. HawkinsInsiderBuy6,000$33.81$202,860.00View SEC Filing  
5/25/2017Doris EngibousDirectorSell5,000$32.68$163,400.00View SEC Filing  
2/9/2017Robert A GunstDirectorSell5,000$36.00$180,000.00View SEC Filing  
12/16/2016James B HawkinsInsiderBuy10,000$35.20$352,000.00View SEC Filing  
10/27/2016James B HawkinsInsiderBuy10,000$38.30$383,000.00View SEC Filing  
10/25/2016Jonathan KennedyCFOSell30,276$41.40$1,253,426.40View SEC Filing  
10/24/2016Jonathan KennedyCFOSell14,138$41.61$588,282.18View SEC Filing  
10/24/2016Robert A GunstDirectorSell3,250$41.92$136,240.00View SEC Filing  
9/28/2016James B HawkinsInsiderBuy10,000$38.48$384,800.00View SEC Filing  
4/26/2016Robert A GunstDirectorSell5,000$34.61$173,050.00View SEC Filing  
4/22/2016Doris EngibousDirectorSell5,000$32.68$163,400.00View SEC Filing  
4/22/2016Kenneth M TraversoVPSell7,459$33.56$250,324.04View SEC Filing  
2/17/2016Ken LudlumDirectorSell6,625$33.02$218,757.50View SEC Filing  
12/9/2015Dong Chune Christopher ChungVPSell14,000$48.78$682,920.00View SEC Filing  
11/27/2015James B. HawkinsCEOSell57,511$49.09$2,823,214.99View SEC Filing  
11/25/2015Austin Francis Noll IIIVPSell38,875$48.40$1,881,550.00View SEC Filing  
11/12/2015James B. HawkinsCEOSell42,489$47.62$2,023,326.18View SEC Filing  
10/30/2015James B. HawkinsCEOSell100,000$45.75$4,575,000.00View SEC Filing  
10/28/2015Dong Chune Christopher ChungVPSell26,000$45.73$1,188,980.00View SEC Filing  
10/28/2015Jonathan KennedyCFOSell28,958$45.72$1,323,959.76View SEC Filing  
9/15/2015William M MooreDirectorSell5,994$40.76$244,315.44View SEC Filing  
9/14/2015William M MooreDirectorSell4,000$40.27$161,080.00View SEC Filing  
9/8/2015William M MooreDirectorSell3,006$40.09$120,510.54View SEC Filing  
8/18/2015William M MooreDirectorSell3,000$45.62$136,860.00View SEC Filing  
8/13/2015William M MooreDirectorSell4,000$45.55$182,200.00View SEC Filing  
7/24/2015Robert A GunstDirectorSell4,000$45.30$181,200.00View SEC Filing  
6/15/2015William M MooreDirectorSell6,000$41.30$247,800.00View SEC Filing  
6/8/2015James B HawkinsCEOSell100,000$42.08$4,208,000.00View SEC Filing  
6/3/2015Dong Chune Christopher ChungVPSell26,000$41.01$1,066,260.00View SEC Filing  
4/28/2015Kenneth M TraversoVPSell57,233$40.80$2,335,106.40View SEC Filing  
4/24/2015Doris EngibousDirectorSell15,000$42.20$633,000.00View SEC Filing  
2/3/2015Dong Chune Christopher ChungVPSell40,000$36.64$1,465,600.00View SEC Filing  
12/9/2014Jonathan KennedyCFOSell45,833$35.67$1,634,863.11View SEC Filing  
12/8/2014William M MooreDirectorSell4,451$34.65$154,227.15View SEC Filing  
12/5/2014William M MooreDirectorSell561$34.65$19,438.65View SEC Filing  
12/2/2014William M MooreDirectorSell2,278$3,478.00$7,922,884.00View SEC Filing  
11/4/2014James B HawkinsCEOSell18,400$34.10$627,440.00View SEC Filing  
10/30/2014Robert A GunstDirectorSell15,000$33.92$508,800.00View SEC Filing  
10/28/2014Dong Chune Christopher ChungVPSell50,000$33.14$1,657,000.00View SEC Filing  
10/28/2014James B HawkinsCEOSell251,600$33.31$8,380,796.00View SEC Filing  
10/27/2014Dong Chune Christopher ChungVPSell39,521$33.09$1,307,749.89View SEC Filing  
10/24/2014Kenneth M TraversoVPSell30,000$33.33$999,900.00View SEC Filing  
9/10/2014William M MooreDirectorSell2,200$29.30$64,460.00View SEC Filing  
9/8/2014William M MooreDirectorSell5,000$29.17$145,850.00View SEC Filing  
7/30/2014Austin Francis Noll IIIVPSell23,500$29.42$691,370.00View SEC Filing  
5/30/2014Ken LudlumDirectorSell2,500$24.77$61,925.00View SEC Filing  
2/24/2014James HawkinsCEOSell75,000$25.88$1,941,000.00View SEC Filing  
2/13/2014James HawkinsCEOSell96,046$24.77$2,379,059.42View SEC Filing  
2/4/2014James HawkinsCEOSell16,910$25.93$438,476.30View SEC Filing  
12/4/2013James HawkinsCEOSell206,878$22.58$4,671,305.24View SEC Filing  
10/29/2013Kenneth M TraversoVPSell25,000$19.54$488,500.00View SEC Filing  
9/12/2013Doris EngibousDirectorSell33,750$13.53$456,637.50View SEC Filing  
9/12/2013Kenneth M TraversoVPSell4,225$13.89$58,685.25View SEC Filing  
8/19/2013Dong Chune Christopher ChungVPSell5,818$12.78$74,354.04View SEC Filing  
8/19/2013James HawkinsCEOSell22,190$12.78$283,588.20View SEC Filing  
6/5/2013Kenneth M TraversoVPSell22,682$14.30$324,352.60View SEC Filing  
6/3/2013Kenneth M TraversoVPSell7,318$14.50$106,111.00View SEC Filing  
5/28/2013Steven J MurphyVPSell10,000$14.42$144,200.00View SEC Filing  
3/12/2013Robert A GunstDirectorBuy5,000$13.40$67,000.00View SEC Filing  
11/27/2012Robert A GunstDirectorBuy10,000$11.66$116,600.00View SEC Filing  
11/9/2012Kenneth M TraversoVPSell49,885$11.19$558,213.15View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Natus Medical (NASDAQ:BABY)
Latest Headlines for Natus Medical (NASDAQ:BABY)
DateHeadline logoAnalyzing Natus Medical (BABY) & Its Rivals - October 20 at 2:28 AM logoNatus Medical Incorporated (BABY) Set to Announce Quarterly Earnings on Wednesday - October 18 at 6:24 AM logoETFs with exposure to Natus Medical, Inc. : October 17, 2017 - October 17 at 5:10 PM logoNatus Medical Incorporated (BABY) Given Average Recommendation of "Hold" by Analysts - October 12 at 12:48 AM logoNatus Medical to Hold 2017 Third Quarter Financial Results Conference Call on October 25th - October 11 at 7:45 AM logoNatus Medical Incorporated (BABY) Scheduled to Post Quarterly Earnings on Tuesday - October 10 at 2:16 AM logoNatus Completes Acquisition of Neurosurgery Assets from Integra ... - GlobeNewswire (press release) - October 7 at 2:38 AM logoETFs with exposure to Natus Medical, Inc. : October 6, 2017 - October 6 at 4:32 PM logoNatus Completes Acquisition of Neurosurgery Assets from Integra LifeSciences - October 6 at 4:32 PM logoIntegra Closes Codman Buyout, Strengthens Neurosurgery Arm - Nasdaq - October 4 at 1:42 PM logoIntegra Closes Codman Buyout, Strengthens Neurosurgery Arm - October 3 at 4:02 PM logoNatus Medical, Inc. :BABY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 - October 2 at 4:14 PM logoBullish Two Hundred Day Moving Average Cross - BABY - September 27 at 7:43 PM logoAnalyzing Natus Medical (BABY) and ViewRay (VRAY) - September 25 at 4:14 AM logoNatus Medical Incorporated (BABY) Expected to Post Quarterly Sales of $121.86 Million - September 18 at 10:48 AM logoNatus Medical Incorporated (BABY) Receives Average Recommendation of "Hold" from Analysts - September 17 at 12:52 AM logoNatus Medical Incorporated (BABY) Expected to Announce Earnings of $0.38 Per Share - September 16 at 8:34 AM logoNatus Medical Incorporated (BABY) Director Sells $154,748.00 in Stock - September 15 at 8:03 PM logoIntegra Divests Assets to Natus, Paves Way for Codman Buyout - Nasdaq - September 13 at 5:31 PM logoIntegra Divests Assets to Natus, Paves Way for Codman Buyout - September 13 at 5:31 PM logoBrokers Issue Forecasts for Natus Medical Incorporated's Q4 2018 Earnings (BABY) - September 13 at 2:30 PM logoNatus Medical, Inc. breached its 50 day moving average in a Bullish Manner : BABY-US : September 12, 2017 - September 12 at 4:33 PM logoBrokers Issue Forecasts for Natus Medical Incorporated's Q4 2017 Earnings (BABY) - September 12 at 8:00 AM logoNatus Medical (BABY) to Acquire Neurosurgery Assets from Integra LifeSciences (IART) for $47.5M - - September 11 at 4:58 PM logoNatus Medical to buy neurosurgery assets from Integra for $47.5M; shares ahead 8% - September 11 at 1:58 PM logoFinancial Comparison: Natus Medical (BABY) and Alliance HealthCare Services (AIQ) - September 10 at 8:24 PM logoDanaher Corporation (DHR) & Natus Medical (BABY) Head to Head Review - September 10 at 12:26 PM logo$121.74 Million in Sales Expected for Natus Medical Incorporated (BABY) This Quarter - August 30 at 1:52 AM logo$0.38 EPS Expected for Natus Medical Incorporated (BABY) This Quarter - August 28 at 8:08 PM logoNatus Medical Incorporated (BABY) Given Consensus Rating of "Hold" by Brokerages - August 23 at 12:30 AM logoNatus Medical Incorporated (BABY) Director William M. Moore Sells 3,000 Shares - August 15 at 8:00 PM logoNatus Medical Incorporated (NASDAQ:BABY) Expected to Announce Quarterly Sales of $121.74 Million - August 12 at 10:16 AM logoNatus Medical, Inc. – Value Analysis (NASDAQ:BABY) : August 11, 2017 - August 11 at 9:54 PM logo Analysts Anticipate Natus Medical Incorporated (NASDAQ:BABY) Will Post Earnings of $0.38 Per Share - August 10 at 2:39 PM logoSee what the IHS Markit Score report has to say about Natus Medical Inc. - August 10 at 2:35 AM logoNatus Medical Incorporated (BABY) Receives Consensus Recommendation of "Hold" from Analysts - July 29 at 12:43 AM logoNatus Medical, Inc. breached its 50 day moving average in a Bearish Manner : BABY-US : July 28, 2017 - July 28 at 5:39 PM logoFY2017 EPS Estimates for Natus Medical Incorporated Decreased by William Blair (BABY) - July 28 at 12:40 PM logoNatus Medical Inc Looks to Turn Things Around - July 27 at 4:40 PM logoEdited Transcript of BABY earnings conference call or presentation 26-Jul-17 3:00pm GMT - July 27 at 2:58 AM logoNatus Medical Announces Second Quarter 2017 Financial Results - July 26 at 4:55 PM logoNatus Medical reports 2Q loss - July 26 at 4:55 PM logoNatus Medical Incorporated (BABY) Posts Earnings Results, Beats Expectations By $0.01 EPS - July 26 at 12:30 PM logoNatus Medical Incorporated (BABY) Releases FY17 Earnings Guidance - July 26 at 11:16 AM logoNatus Medical Incorporated (NASDAQ:BABY) Issues Q3 Earnings Guidance - July 26 at 11:16 AM logoRobbins Arroyo LLP Is Investigating the Officers and Directors of Natus Medical Incorporated (BABY) on Behalf of ... - Business Wire (press release) - July 21 at 5:54 PM logoRobbins Arroyo LLP Is Investigating the Officers and Directors of Natus Medical Incorporated (BABY) on Behalf of Shareholders - July 21 at 5:54 PM logoNatus Medical Inc (NASDAQ:BABY) Scheduled to Post Quarterly Earnings on Tuesday - July 14 at 8:02 AM logoNotable Thursday Option Activity: BABY, CARB, MA - - Nasdaq - July 13 at 10:15 PM logoNatus Medical to Hold 2017 Second Quarter Financial Results Conference Call on July 26th - Nasdaq - July 13 at 5:10 PM



Natus Medical (BABY) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.